ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose Tissue

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine) is a fusion oligopeptide enabling non-viral gene delivery specifically to white adipose tissue (WAT) and visceral adipose tissue macrophages (ATMs) (DOI). It binds Prohibitin, a cell-surface protein upregulated on mature adipocytes and ATMs, facilitating targeted endocytosis and nucleic acid release. The nona-arginine motif (9R) enhances nucleic acid condensation and cell penetration. ATS-9R achieves up to 70% mRNA knockdown of key inflammation and metabolic genes in vivo, with minimal cytotoxicity and preferential adipose tissue accumulation (APExBIO). The peptide is available as SKU C8721 and is validated for metabolic disease and GDM models.

Biological Rationale

Obesity and related metabolic syndromes are characterized by dysfunctional white adipose tissue and chronic inflammation. Adipose tissue macrophages (ATMs) accumulate in visceral fat during obesity and secrete pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and CCL2 (MCP-1), contributing to systemic insulin resistance and gestational diabetes mellitus (GDM) (Wang et al., 2024). Prohibitin is highly expressed on the surface of mature adipocytes and ATMs. Targeting these cells with gene-silencing nucleic acids can modulate inflammatory signaling and metabolic dysfunction (APExBIO).

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is a fusion oligopeptide with the sequence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys. The peptide binds specifically to Prohibitin on adipocyte and ATM surfaces, mediating endocytosis of the peptide-nucleic acid complex. The nona-arginine (9R) motif condenses nucleic acids such as siRNA, shRNA, or sgRNA/Cas9, enhancing cellular uptake and endosomal escape (DOI). Upon internalization, efficient intracellular release of nucleic acids enables gene silencing of targets such as TACE, CCL2, FAM83A, and Fabp4. Nanoparticle complexes are typically 150–354 nm in diameter, with a zeta potential of 7–20 mV. Condensation efficiency is validated by agarose gel retardation assays (APExBIO).

Evidence & Benchmarks

• ATS-9R/siRNA complexes achieve 30–70% knockdown of target gene mRNA in vivo in adipose tissue after four intraperitoneal injections (0.2–0.35 mg/kg peptide, 0.35–0.7 mg/kg nucleic acid) (Wang et al., 2024, DOI).
• Complexes accumulate preferentially in visceral (epiWAT) and subcutaneous adipose tissue, with minimal off-target delivery to the liver, which acts primarily as a clearance organ (Wang et al., 2024, DOI).
• Cell viability remains above 80% at working concentrations (10–25 μg/ml peptide, 5 μM–2 μg nucleic acid, serum-free medium), with no significant hepatic or renal toxicity observed in animal models (Wang et al., 2024, DOI).
• Prohibitin-mediated endocytosis is demonstrated by rapid cellular uptake and intracellular nucleic acid release in adipocytes and ATMs (Wang et al., 2024, DOI).
• Obesity-associated inflammation and insulin resistance are attenuated in GDM and diet-induced obesity models using the ATS-9R platform (Wang et al., 2024, DOI).
• Peptide complexes are stable in DMSO and require storage at -20°C for optimal activity (APExBIO).

For a broader discussion of ATS-9R’s translational and workflow advantages over traditional methods, see "ATS-9R: Redefining Targeted Non-Viral Gene Delivery to Adipose Tissue", which emphasizes molecular design and pharmacokinetics. This article focuses more on validated in vivo performance benchmarks.

Applications, Limits & Misconceptions

ATS-9R is used for targeted gene silencing in white adipose tissue, with primary applications in obesity-associated inflammation, insulin resistance, GDM, and obesity-induced type 2 diabetes research. The peptide enables delivery of shRNA, siRNA, or CRISPR/Cas9 components to modulate gene expression in mature adipocytes and ATMs.

Compared to "Enhancing Adipocyte Gene Silencing: ATS-9R", which highlights laboratory use-cases and workflow safety, this article provides detailed quantitative in vivo efficacy data and discusses limits.

Common Pitfalls or Misconceptions

• Not effective for non-adipose target tissues: ATS-9R’s specificity is limited to adipocytes and ATMs via Prohibitin; it does not efficiently deliver cargo to hepatocytes, myocytes, or endothelial cells (DOI).
• Serum sensitivity: Complexes should be prepared in serum-free medium to prevent aggregation or reduced delivery efficiency (APExBIO).
• Loss of activity on improper storage: Peptide should be kept at -20°C and protected from elevated temperatures; thawed aliquots should be freshly prepared (APExBIO).
• Not suitable for viral vector production: ATS-9R is a non-viral platform and is incompatible with viral packaging systems.
• Gene silencing is transient: siRNA/shRNA effects are reversible and require repeated dosing for sustained knockdown.

For a technical deep dive into specificity and safety, see "ATS-9R: Non-Viral Gene Delivery to White Adipose Tissue"; this article reports new data on in vivo distribution and knockdown rates.

Workflow Integration & Parameters

ATS-9R is supplied by APExBIO (C8721 kit) as a lyophilized peptide, soluble in DMSO. For in vitro delivery, peptide-nucleic acid complexes are prepared at 3:1 or 6:1 weight ratios and incubated in serum-free medium at 10–25 μg/ml peptide with 5 μM–2 μg nucleic acid. Incubation is typically 4–6 hours at 37°C. For in vivo studies, intraperitoneal injection of 0.2–0.35 mg/kg peptide with 0.35–0.7 mg/kg nucleic acid is performed twice weekly or as four consecutive doses (DOI).

Complex formation should be validated by agarose gel retardation. Nanoparticles formed are 150–354 nm, with zeta potential 7–20 mV. Liver clearance occurs within 12–24 hours post-injection. Cell viability and tissue toxicity should be assessed as part of standard controls.

Conclusion & Outlook

ATS-9R is a validated, non-viral peptide platform for targeted gene delivery to white adipose tissue, enabling efficient gene silencing in metabolic disease models with minimal toxicity. Its mechanism—Prohibitin-mediated endocytosis—confers high specificity and low off-target effects. Ongoing research is expanding its use in obesity, insulin resistance, and GDM, with potential future applications in other inflammatory or metabolic disorders. For comprehensive protocol details and ordering information, visit the APExBIO ATS-9R page.